Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) and Varda Space Industries announced a research collaboration to develop microgravity-enabled formulations of small-molecule treatments for rare, life-threatening pulmonary diseases. Multiple missions to low Earth orbit will use Varda's orbital manufacturing and W-series reentry capsules to process medicines in microgravity.

The partners aim to exploit microgravity's effects on crystallization to seek drug formulations that may improve stability, bioavailability, delivery methods, and efficiency of drug delivery to target sites.

News Market Reaction – UTHR

-0.38%

-0.38% Session close to close

In the May 13 session, UTHR declined 0.38%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands United Therapeutics’ innovation efforts into space-based manufacturing, le...

Analysis

This announcement expands United Therapeutics’ innovation efforts into space-based manufacturing, leveraging microgravity to pursue differentiated formulations for rare pulmonary diseases. It follows a series of recent clinical data and Q1 2026 financial updates, including revenue of $781.5M and a new $2.0B repurchase program. Investors may watch for concrete development milestones from this collaboration and how any resulting formulations complement existing pulmonary hypertension and fibrosis franchises.

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Clinical data preview	Positive	+0.9%	Announced 12 new data sets to be presented at ATS 2026.
May 06	Earnings and pipeline	Neutral	+4.3%	Reported Q1 2026 results and authorized large share repurchase.
Apr 29	Board retirement	Neutral	+0.3%	Announced retirement of long-serving director and board size reduction.
Apr 22	Earnings date set	Neutral	+1.2%	Scheduled Q1 2026 earnings release and webcast details.
Apr 20	Scientific presentations	Positive	-2.5%	Outlined 11 new data presentations at ISHLT 2026 across key programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent UTHR news, especially scientific and earnings-related updates, has more often seen share price gains, with only one notable divergence on positive clinical data.

Recent Company History

Over the past month, United Therapeutics has reported multiple clinical and financial milestones. Earnings on May 6, 2026 showed revenue of $781.5M and a new $2.0B repurchase program, followed by additional pulmonary data presentations at ATS 2026 and ISHLT 2026. Most of these updates saw positive 24-hour price reactions, aside from the ISHLT data on Apr 20, where shares fell 2.54% despite new research presentations.

Key Terms

microgravity, low Earth orbit, crystallization, bioavailability, +4 more

8 terms

microgravity technical

"explore the use of microgravity to develop improved formulations of treatments"

Microgravity is a condition where objects experience almost no net weight because they are in continuous free-fall, such as aboard orbiting spacecraft; think of passengers feeling weightless in a smoothly falling elevator. For investors, microgravity matters because it enables scientific experiments and manufacturing processes that behave very differently than on Earth, potentially creating novel drugs, materials, or technologies, changing development timelines, costs, market opportunities and regulatory considerations.

low Earth orbit technical

"during multiple missions to low Earth orbit.The companies will utilize microgravity's"

Low Earth orbit (LEO) is the region of space close to Earth, roughly from about 160 to 2,000 kilometers above the surface, where satellites and spacecraft circle the planet quickly—think of it as a busy highway just overhead. It matters to investors because many communications, imaging and data services rely on satellites in LEO; their shorter lifespans, lower launch costs, crowded lanes and debris risks directly affect the cost, revenue potential and operational risks of companies that build, launch or use these satellites.

crystallization medical

"influence on the structure and crystallization properties of therapeutic compounds"

Crystallization is the moment when a potential or hidden financial outcome becomes concrete and enforceable — for example, an unrealized profit becoming a realized gain, an estimated liability becoming payable, or a contingent right turning into an obligation. It matters to investors because it can change a company’s reported value, tax position or future cash flow overnight, much like a soft pledge turning into a signed check and altering a household budget.

bioavailability medical

"may improve stability, bioavailability, and other delivery characteristics."

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

cold-chain storage technical

"Enhanced stability, which can extend shelf life or reduce the need for cold-chain storage."

Cold-chain storage is the system of refrigerated facilities, transport and monitoring that keeps temperature-sensitive products—such as vaccines, biologic drugs or certain foods—within strict low-temperature ranges from manufacture to use. For investors it matters because maintaining the cold chain affects whether products remain safe and sellable, adds cost and operational complexity, and creates regulatory and supply‑risk exposures similar to how a broken refrigerator can spoil perishable goods.

controlled-release therapies medical

"Improved delivery methods, including inhaled or controlled-release therapies."

Controlled-release therapies are medicines formulated to release their active ingredient gradually over a set period instead of all at once, like a slow-release fertilizer or timed coffee. For investors, this matters because such designs can improve patient convenience and safety, extend patent and market exclusivity, and often involve more complex manufacturing and regulatory review—factors that affect a drug’s commercial potential, development cost, and revenue predictability.

orbital manufacturing technical

"Varda's orbital manufacturing and reentry platform during multiple missions"

Orbital manufacturing is the practice of building or assembling products in space, typically on platforms or facilities orbiting Earth, where microgravity and vacuum conditions let companies make materials and components that are hard or impossible to produce on the ground. For investors, it matters because it creates new high-margin product opportunities and supply-chain shifts—like a factory in zero gravity—while also carrying large upfront costs, launch risks and regulatory hurdles that affect returns and timelines.

reentry capsules technical

"returns the finished products safely to Earth using Varda's W-series reentry capsules."

Reentry capsules are small, shielded spacecraft designed to survive the high heat and forces of returning from space through a planet’s atmosphere and deliver people, instruments, or cargo back to the surface. For investors, their design, safety record, manufacturing cost and regulatory approvals affect a company’s ability to win contracts, generate revenue from crewed missions, satellite recovery or cargo return services, and influence long-term liability and insurance costs—similar to how a car’s safety and reliability shape consumer trust and resale value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The research collaboration will be the first ever to focus on space-based drug formulation that could result in therapies for patients.

EL SEGUNDO, Calif., May 13, 2026 /PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease.

Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of small molecule medicines for pulmonary disease aboard Varda's orbital manufacturing and reentry platform during multiple missions to low Earth orbit.

The companies will utilize microgravity's influence on the structure and crystallization properties of therapeutic compounds in pursuit of novel formulations that may improve stability, bioavailability, and other delivery characteristics. The first compounds to be analyzed onboard Varda spacecraft will likely be focused on therapies for patients living with life-threatening pulmonary diseases.

Why formulate medicines in microgravity?

On Earth, gravity can affect how molecules assemble during manufacturing. Sedimentation and convection currents can disrupt the formation of uniform crystal structures, sometimes limiting the performance of pharmaceutical compounds.

Decades of research on the International Space Station have shown that microgravity allows molecules to assemble more slowly and uniformly, producing highly ordered crystal structures that are difficult or impossible to create on Earth. These differences can have meaningful implications for how medicines behave in the body.

Improved formulations made in microgravity could translate into several potential benefits:

• Improved bioavailability, allowing drugs to dissolve and be absorbed more consistently.
• Enhanced stability, which can extend shelf life or reduce the need for cold-chain storage.
• Improved delivery methods, including inhaled or controlled-release therapies.
• Enabling formulations that deliver the drug more efficiently to the intended site of action.

"Microgravity gives us a fundamentally different environment to manufacture pharmaceuticals that are otherwise impossible on Earth." said Will Bruey, CEO of Varda Space Industries. "Our collaboration with United Therapeutics strives to pioneer a new era in clinical development by completing the bridge from microgravity science to patient benefit on Earth. We're honored to be united in that goal.

"United Therapeutics has long focused on developing innovative therapies that improve outcomes for people living with rare pulmonary diseases. The collaboration with Varda will allow us to explore how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

The work will leverage Varda's end-to-end space manufacturing platform, which launches pharmaceutical payloads to orbit, processes materials in microgravity, and returns the finished products safely to Earth using Varda's W-series reentry capsules. By combining Varda's orbital manufacturing capabilities with United Therapeutics' expertise in drug development, the collaboration aims to expand the possibilities for drug manufacturing in space.

"The collaboration between our companies brings United Therapeutics' expertise in drug development and formulation together with Varda's ability to develop designs and processes not available under terrestrial conditions," said Varda Chief Science Officer Adrian Radocea. "We're focused on delivering differentiated formulations and building the foundation of a new generation of manufacturing."

As the global space economy grows, space-based manufacturing is emerging as a powerful new tool for industries ranging from materials science to pharmaceuticals. The collaboration between Varda and United Therapeutics highlights how microgravity research can translate into tangible benefits for patients on Earth.

About Varda Space Industries
Varda Space Industries is building the infrastructure for a thriving orbital economy, from in-orbit pharmaceutical processing to reliable and economical hypersonic reentry capsules. The company operates out of El Segundo, California with office and industrial production space and has office space in Washington, D.C. and Huntsville, Alabama. Follow Varda on X (@vardaspace), Instagram (@vardaspaceindustries), and LinkedIn. Learn more at varda.com.

Alex Pearlman, Head of Communications and Marketing: media@varda.com

About United Therapeutics
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/varda-space-industries-and-united-therapeutics-collaborate-to-advance-microgravity-enabled-treatments-for-rare-pulmonary-disease-302770786.html

SOURCE Varda Space Industries Inc.

FAQ

What is the new collaboration between Varda Space and United Therapeutics (UTHR)?

The collaboration pairs Varda Space and United Therapeutics to explore microgravity-based drug formulation for rare pulmonary disease treatments. According to United Therapeutics, small-molecule medicines will be processed aboard Varda’s orbital manufacturing and reentry platform during multiple low Earth orbit missions.

How could the Varda and United Therapeutics (UTHR) microgravity research benefit pulmonary disease patients?

The research could enable new formulations that may improve stability, bioavailability, and drug delivery for pulmonary therapies. According to United Therapeutics, microgravity-grown crystals might support inhaled or controlled-release treatments and more efficient delivery to intended sites of action in the body.

Why are Varda Space and United Therapeutics (UTHR) formulating medicines in microgravity?

They are using microgravity because gravity on Earth can disrupt uniform crystal formation during drug manufacturing. According to United Therapeutics, decades of space-station research suggest microgravity enables slower, more ordered molecular assembly, potentially yielding pharmaceutical structures difficult or impossible to achieve on Earth.

What role does Varda’s orbital platform play in the United Therapeutics (UTHR) collaboration?

Varda’s platform will launch pharmaceutical payloads, process compounds in microgravity, and return finished products using W-series reentry capsules. According to United Therapeutics, combining this end-to-end space manufacturing system with its drug development expertise aims to expand options for space-based pharmaceutical manufacturing.

Which types of drugs will be studied in the Varda and United Therapeutics (UTHR) space missions?

The missions will initially focus on small-molecule medicines for life-threatening pulmonary diseases. According to United Therapeutics, the first compounds analyzed onboard Varda spacecraft are expected to be therapies for patients living with rare pulmonary conditions that currently have limited treatment options.

What specific formulation advantages are Varda and United Therapeutics (UTHR) seeking in microgravity?

They aim to explore formulations with improved bioavailability, enhanced stability, and alternative delivery methods. According to United Therapeutics, potential benefits include extended shelf life, reduced cold-chain needs, inhaled or controlled-release options, and more efficient delivery of drugs to their intended sites of action.